Nuvectis Pharma, Inc.
NVCT evidence brief
What we can confirm
- BioSniper Score:
- 6.1 / 10
- Market Cap:
- $783.1M
- Lead Asset:
- nxp800 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for NVCT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NVCT
Nuvectis Pharma, Inc. (NVCT) is a pre-revenue, clinical-stage biotechnology company focused on developing small-molecule kinase inhibitors for advanced cancers, with lead candidate NXP900 in Phase 1b combination trials.
Key risk: No revenue or approved products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials for Nuvectis Pharma, Inc..
Nuvectis Pharma, Inc. (NVCT) is a pre-revenue, clinical-stage biotechnology company focused on developing small-molecule kinase inhibitors for advanced cancers, with lead candidate NXP900 in Phase 1b combination trials.
- Cash and equivalents of $22.2M as of 2026-06-30 [sec].
- Net loss of -$7.0M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $9.1M as of 2026-06-30 [sec].
- Lead drug candidate NXP900, a SRC Family Kinase inhibitor, is in Phase 1b combination studies with osimertinib (EGFR) and pending with lorlatinib (ALK) for non-small cell lung cancer [sec · filed 2026-08-21].
- No products approved for sale and no revenue from product sales generated to date [sec_mda · as of 2026-02-11].
What works
- NXP900 has completed a Phase 1a dose escalation study with acceptable safety and robust pharmacodynamic response at clinically relevant doses, supporting advancement into Phase 1b [news · published 2025-05-06].
- The company has in-licensed four drug candidates (NXP100, NXP200, NXP900, NXP800) and secured related intellectual property rights, building a pipeline of kinase inhibitors [sec_mda · as of 2026-08-04].
- Nuvectis strengthened its cash position via a $15.5M financing in early 2025 and an ATM shares acquisition by a healthcare-dedicated institutional investor, extending projected cash runway into 1Q2027 [news · published 2025-05-06].
What to weigh
- The company has no approved products and has not generated any revenue from product sales; it may never develop or commercialize a marketable product [sec_mda · as of 2026-02-11].
- Nuvectis has not yet successfully completed any pivotal clinical trials, obtained regulatory approvals, or conducted commercial-scale manufacturing or sales [sec_mda · as of 2026-02-11].
- The company reported a net loss of -$7.0M for the period ended 2026-06-30, reflecting ongoing R&D and operational expenses without offsetting revenue [sec].
- All drug candidates are in early clinical or preclinical stages, with NXP900 only recently entering Phase 1b combination studies, meaning significant development and regulatory risk remain [sec · filed 2026-08-21].
From the filings
Quoted directly from source documents.
Nuvectis has no approved products and no revenue from product sales.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · February 11, 2026
NXP900 is a SRC Family Kinase inhibitor in Phase 1b combination studies.
“NXP900, a SRC Family Kinase ("SFK") inhibitor that potently inhibits the c-Src ("SRC") and YES1 kinases.”
SEC filings · August 21, 2026
Catalyst timeline
- 2025-12-18 · Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer — This combination study is ongoing; data on safety and preliminary efficacy will be key to advancing the program.
- 2026-08-17 · Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer — This study is pending commencement; its initiation will expand NXP900's clinical evaluation into ALK-driven NSCLC.
Risks & what to watch (4)›
Key risks
- No revenue or approved products — Company has no approved products and no revenue from sales; may never commercialize a product [sec_mda · as of 2026-02-11].
- Early-stage pipeline
- Net losses and cash burn — Net loss of $7.0M as of 2026-06-30 with no offsetting revenue; cash of $22.2M may fund operations only into 2027 [sec].
- Regulatory and development risk — No regulatory approvals obtained; all drug candidates face significant clinical and regulatory hurdles [sec_mda · as of 2026-02-11].
What to watch
- Enrollment and preliminary efficacy data from the NXP900 Phase 1b combination study with osimertinib (EGFR) in NSCLC, which commenced in December 2025 [catalyst].
- Initiation and early results of the NXP900 Phase 1b combination study with lorlatinib (ALK) in ALK-positive NSCLC, pending commencement as of August 2026 [catalyst].
- Cash runway updates: as of June 30, 2026, cash was $22.2M; watch for future financing rounds or ATM draws to extend operations [sec].
- Any regulatory milestones or updates on NXP800, the other clinical-stage candidate, which began Phase 1 in 2021 [catalyst].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Nuvectis Pharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Nuvectis Pharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.46 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
62
Total value held
$34.7M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 764,441 | $5.9M |
| vanguard capital management llc | 659,879 | $5.1M |
| iridian asset management llc/ct | 651,757 | $5.0M |
| occam crest management lp | 407,147 | $3.1M |
| geode capital management, llc | 384,105 | $3.0M |
| baldwin wealth partners llc/ma | 378,625 | $2.9M |
| state street corp | 166,516 | $1.3M |
| northern trust corp | 124,212 | $960K |
| vanguard fiduciary trust co | 114,842 | $888K |
| susquehanna international group, llp | 105,286 | $814K |
Showing top 10 of 62 institutional holders of Nuvectis Pharma, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 10.0%
- Days to cover
- 25.5
- Shares short
- 1,541,168
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NVCT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Nuvectis Pharma, Inc.?
Nuvectis Pharma, Inc. (NVCT) is a pre-revenue, clinical-stage biotechnology company focused on developing small-molecule kinase inhibitors for advanced cancers, with lead candidate NXP900 in Phase 1b combination trials.
What is Nuvectis Pharma, Inc.'s lead drug candidate?
Nuvectis Pharma, Inc.'s most advanced tracked candidate is nxp800 (Phase 1) for Advanced Solid Tumor.
Who is the CEO of Nuvectis Pharma, Inc.?
Mr. Ron Bentsur M.B.A. is the chief executive officer of Nuvectis Pharma, Inc. (NVCT).
Where is Nuvectis Pharma, Inc. headquartered?
Nuvectis Pharma, Inc. (NVCT) is headquartered in Fort Lee, NJ, United States.
What therapeutic areas does Nuvectis Pharma, Inc. focus on?
Nuvectis Pharma, Inc. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.